Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05859698 · ClinicalTrials.gov registry record · Phase 4
Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia
A Phase 4 study, sponsored by Neurocrine Biosciences.
- Completed
- Registry status
- Phase 4
- Development phase
- 59
- Enrollment target
NCT05859698 is a Phase 4 study that has completed, run by Neurocrine Biosciences. The registered enrollment target is 59 participants.
The verdict
NCT05859698, a Phase 4 study, has completed, sponsored by Neurocrine Biosciences.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 59 participants
- Enrollment target
Study Summary
This study will evaluate the effectiveness of valbenazine on patient- and clinician-reported outcomes assessing health-related quality of life, functioning, and treatment effect in participants with tardive dyskinesia (TD) who are receiving valbenazine for up to 24 weeks.
Interventions
- DRUG Valbenazine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2023-05-09 |
| Est. Completion | 2024-12-27 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05859698
The ClinicalTrials.gov registry entry for NCT05859698 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Neurocrine Biosciences, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Valbenazine is the first listed.
NCT05859698 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05859698 about?
NCT05859698 is a clinical study titled "Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia". This study will evaluate the effectiveness of valbenazine on patient- and clinician-reported outcomes assessing health-related quality of life, functioning, and treatment effect in participants with tardive dyskinesia (TD) who are receiving valbenazine for up to 24 weeks.
What is the current status of trial NCT05859698?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 59 participants. The study started on 2023-05-09. Estimated completion is 2024-12-27.
What interventions are being tested in trial NCT05859698?
The interventions under investigation include: Valbenazine (DRUG).
Who is sponsoring clinical trial NCT05859698?
This trial is sponsored by Neurocrine Biosciences, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.